Overexpression of CARM1 in breast cancer is correlated with poorly characterized clinicopathologic parameters and molecular subtypes

Table 2 Correlation between cytoplasmic CARM1 expression and the clinicopathologic characteristics of breast cancer patients

Clinicopathologic characteristics	n	Cytoplasmic CARM1 expression		P*
Clinicopathologic characteristics	n	Negative or low expression (IHC score < 80)	High or over expression (IHC score ≥ 80)	P*
Age(y)
≤40	53	16 (30.2)	37 (69.8)	0.041
>40	194	89 (45.9)	105 (54.1)
Tumor size
≤2 cm	125	57 (45.6)	68 (54.4)	0.320
>2 cm	122	48 (39.3)	74 (60.7)
Tumor number
1	234	101 (43.2)	133 (56.8)	0.379
≥2	13	4 (30.8)	9 (69.2)
Grade
I&II	181	85 (47.0)	96 (53.0)	0.019
III	66	20 (30.3)	46 (69.7)
Lymph node metastasis
N0	127	48 (37.8)	79 (62.2)	0.123
N1, N2,N3	120	57 (47.5)	63 (52.5)
TNM stage
I	74	30 (40.5)	44 (59.5)	0.384
II	111	44 (39.6)	67 (60.4)
III	62	31 (50.0)	31 (50.0)
ER
negative	90	28 (31.1)	62 (68.9)	0.006
positive	157	77 (49.0)	80 (51.0)
PR
negative	136	50 (36.8)	86 (63.2)	0.043
positive	111	55 (49.5)	56 (50.5)
HER2
negative	206	93 (45.1)	113 (54.9)	0.060
positive	41	12 (29.3)	29 (70.7)
Expression of K-i67
low (≤10%)	55	31 (56.4)	24 (43.6)	0.018
high (>10%)	192	74 (38.5)	118 (61.5)
Expression of P53
low	95	45 (47.4)	50 (53.6)	0.222
high	152	60 (39.5)	92 (60.5)

* P value is the result of χ² test in the same factor, and < 0.05 is considered statistically significant.

ISSN: 1746-1596